An observational study in Gastric Cancer, Neoadjuvant Chemotherapy and Neoadjuvant Chemoradiotherapy, sponsored by Peking University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2018-04-11.
Sponsored by Peking University · Observational
Among 43 studies in Stomach Neoplasms by Peking University — 10 open to participants now, 11 under way, none of them phase 3. Stomach Neoplasms · Peking University.
Among the 43 studies in Stomach Neoplasms by Peking University, this one is the 4th largest by planned enrollment of the 14 observational ones, is one of 3 that started in 2015, is one of 14 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 23rd registered.
3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.
This study's planned enrollment of 600 is above the median of 278 across 790 observational studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →10 of the 43 studies in Stomach Neoplasms by Peking University are open now, in 1 country. Each count lists the studies.
Of the 702 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 68 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →43 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2015.
Median enrollment 64 across the 29 interventional studies, 300 across the 14 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
Peking University is the lead sponsor of 419 studies on the registry; 123 are open to participants now.
3 of the studies in Stomach Neoplasms by Peking University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06893133Peking UniversityctDNA-MRD Monitoring After Resection in Gastric Cancer | 2026-12-30 |
| NCT06384300Peking UniversityFinancial Incentives and Motivational Intervention to Improve Gastric Cancer Screening in China | 2027-01-31 |
| NCT06134960Peking UniversityNKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor | 2027-06-30 |
Among the 43 studies in Stomach Neoplasms by Peking University, from their registry updates:
Nothing recorded among them since 2026-09-25.
Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer. With the increasing application of preoperative treatments (chemotherapy and chemoradiotherapy), the issues concerning how are the immuno-nutrition index be altered under the effects of perioperative treatments and what are the clinical values of these index should be clarified.
The immune (systemic inflammation) index includes:
NLR (Neutrophil-to-Lymphocyte Ratio); PLR (Platelet-to-Lymphocyte Ratio); SII (Systemic Immune-Inflammation Index); GPS (Glasgow Prognostic Score); mGPS (modified Glasgow Prognostic Score); PI (Prognostic Index);
The nutrition index includes:
NRS2002; PNI (Prognostic Nutrition Index);
All the patients with advanced gastric cancer or esophagogastric cancer receiving neoadjuvant chemotherapy or chemoradiotherapy will be included for this observational study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.
Pathological response
Pathological response
Time frame: One month after surgery
3-years overall survival
3-years overall survival
Time frame: Three years after surgery
3-years disease-free survival
3-years disease-free survival
Time frame: Three years after surgery
Postoperative morbidity
Postoperative morbidity
Time frame: One month after surgery
yp TNM Stage
yp TNM Stage
Time frame: One month after surgery
Started Sep 2015 (actual). Primary completion is estimated for Sep 2020, 60 months after the start.
Of 322 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 60 months is close to that.
Counting every sponsor, half of 364 studies reached it within 54 months; a quarter within 29 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.